Evidence map›Paper›PMID 30693467›Full record

ArticleClinical and experimental immunology2019

Natural killer cell expression of Ki67 is associated with elevated serum IL-15, disease activity and nephritis in systemic lupus erythematosus.

K Hudspeth, S Wang, J Wang, S Rahman, M A Smith, K A Casey, Autoimmunity Molecular Team, Z Manna, M Sanjuan, R Kolbeck and 3 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Increased ILT2Clinical rheumatology · 2023
    Article
  9. The effect of PD-1/PD-L1 signaling axis on the interaction between CD19Advances in rheumatology (London, England) · 2023
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Activation status of CD56Clinical rheumatology · 2021
    Article
  16. Article
  17. Review
  18. Natural killer cells in inflammatory autoimmune diseases.Clinical & translational immunology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

K HudspethImmunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-2673-688X
S WangRespiratory, Inflammation, and Autoimmunity Group, MedImmune LLC, Gaithersburg, MD, USA.
J WangRespiratory, Inflammation, and Autoimmunity Group, MedImmune LLC, Gaithersburg, MD, USA.
S RahmanRespiratory, Inflammation, and Autoimmunity Group, MedImmune LLC, Gaithersburg, MD, USA.
M A SmithRespiratory, Inflammation, and Autoimmunity Group, MedImmune LLC, Gaithersburg, MD, USA.
K A CaseyRespiratory, Inflammation, and Autoimmunity Group, MedImmune LLC, Gaithersburg, MD, USA.
Autoimmunity Molecular TeamRespiratory, Inflammation, and Autoimmunity Group, MedImmune LLC, Gaithersburg, MD, USA.
Z MannaOffice of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health, Bethesda, Maryland, USA.
M SanjuanRespiratory, Inflammation, and Autoimmunity Group, MedImmune LLC, Gaithersburg, MD, USA.
R KolbeckRespiratory, Inflammation, and Autoimmunity Group, MedImmune LLC, Gaithersburg, MD, USA.
S HasniOffice of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health, Bethesda, Maryland, USA.
R EttingerRespiratory, Inflammation, and Autoimmunity Group, MedImmune LLC, Gaithersburg, MD, USA.
R M SiegelImmunoregulation Section, Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-5953-9893
National Institutes of Health · USNovartis (Switzerland) · CHBristol-Myers Squibb (United States) · US

Funding

TNF-receptors and programmed cell death in regulation of autoimmunityZIAAR041133 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI SIEGEL, RICHARD M · 2009 to 2019
$9.3M
6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a complex autoimmune disorder whose pathology involves multiple immune cell types, including B and T lymphocytes as well as myeloid cells. While it is clear that autoantibody-producing B cells, as well as CD4

Indexed as

AdolescentAdultAgedCD56 AntigenCells, CulturedFemaleHumansImmunity, InnateInterleukin-15Ki-67 AntigenKiller Cells, NaturalLeukopeniaLupus Erythematosus, SystemicMaleMiddle AgedNephritisCD56 AntigenIL15 protein, humanInterleukin-15Ki-67 AntigenMKI67 protein, human

Identifiers

PMID30693467
PMCPMC6468178
OpenAlexW2911749376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.